The Role of Ceus in the Characterization of Focal Liver Lesions Indeterminate to Second-level Methods
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Mar 10, 2025
Trial Information
Current as of July 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a method called Contrast-Enhanced Ultrasound (CEUS) to see how well it can help doctors determine whether certain liver growths, known as focal liver lesions, are benign (not harmful) or malignant (cancerous). Sometimes, other imaging tests like CT scans, MRIs, or PET scans don’t provide clear answers about these lesions, and this study aims to find out if CEUS can provide more accurate information.
To participate in this trial, individuals need to be at least 18 years old and have had a CEUS in the past six months where other imaging tests were inconclusive. Participants will undergo the CEUS procedure, and they will need to give their consent to join the study. It's important to note that people who cannot have the ultrasound for technical reasons or who are allergic to the contrast fluid used in the ultrasound will not be eligible. This study is currently recruiting participants of all genders, and it hopes to improve the way doctors understand and treat liver lesions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years.
- • CEUS performed performed in the last 6 months a CT, MRI and/or PET not decisive in characterizing a liver lesion.
- • Obtaining informed consent.
- Exclusion Criteria:
- • Technical impossibility to perform the ultrasound evaluation.
- • Documented allergy to the ultrasound contrast medium.
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Carla Serra, PhD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported